Estimate delivery
Actual EPS versus consensus
Actual and estimated EPS are displayed in reported currency on the same quarterly basis.
US Equity · NASDAQ · Earnings Dossier
GENB earnings intelligence
Generate Biomedicines, Inc. Common StockHealthcare · Biotechnology · USD reporting basis
Current earnings profile
Evidence is still developing
More reported quarters are needed before delivery consistency can be assessed reliably.
Evidence81/100 · Strong
Next scheduled catalyst
Thursday 5 November 2026
Time unconfirmed · Fiscal period ending 30 Sep 2026
52event risk
Elevated
Countdown21 dayscalendar proximity
EPS estimate-0.50 USDprovider consensus
Estimate growth-versus comparable year-ago actual
Historical movement3.2%average absolute next weekly close
Three-year earnings transmission
Delivered earnings power versus market price
Three-year relationship unavailable
A full 156-week price window is needed.
Beat rate0.0%0 beats in 2 measured quarters
Average surprise-59.1%median -59.1%
Delivery streak22 consecutive misses
Average response+3.2%2 measured reactions
Result-price confirmation0%same directional sign
Surprise variability50.7 ptspopulation dispersion
Price acceptance
Surprise and next weekly close
The response uses the first completed weekly close after the public report against the prior completed weekly close.
Fundamental delivery
Quarterly revenue and net income
Reported financial statements provide scale and earnings quality context around the headline EPS result.
Transmission matrix
Does price confirm delivery?
Upper right and lower left observations confirm the sign of delivery. The other quadrants expose expectation or resilience effects.
Current business context
Growth, quality and valuation
EPS growth-year on year
Revenue growth55.9%year on year
Average surprise-59.1%latest four quarters
SUE-0.82standardised surprise
Net margin-637.0%trailing basis
Cash conversion1.00xcash flow / net income
P/E-current snapshot
Data completeness71%alphavantage
Market context
Positioning into the event
Weekly close14.34 USDcompleted week
13-week return0.1%price momentum
Fair-value gap1.9%price versus current fair value
Relative strength-exchange benchmark
Trend signalActiveweekly architecture
Next-week stateUndecided49.8%
Market context describes the setup surrounding the report. It does not convert the earnings event into a directional forecast.
Reported evidence ledger
Quarter-by-quarter delivery and acceptance
Each row preserves the reported estimate, public date, statement context and conservative weekly reaction measurement.
Reported / periodEPS actual / estimateSurpriseEPS growthRevenue / growthNext close / four weeksRead
Reported / period6 Aug 202630 Jun 2026 · exact
EPS actual / estimate-0.52 / -0.48USD
Surprise-8.3%Miss
EPS growth-year on year
Revenue / growth6314000-37.7% · USD
Next close / four weeks+2.5% / +9.5%completed weekly closes
ReadDivergedresult versus price sign
Reported / period7 May 202631 Mar 2026 · exact
EPS actual / estimate-1.07 / -0.51USD
Surprise-109.8%Miss
EPS growth-year on year
Revenue / growth7224000-18.1% · USD
Next close / four weeks+3.9% / -0.2%completed weekly closes
ReadDivergedresult versus price sign
Reproducible method
How the earnings dossier is measured
Reported diluted EPS is compared with the stored estimate for the same fiscal period. Moves within ±0.5% are classified as in-line.
The first completed weekly close after the public date is compared with the prior completed weekly close. Four-week response uses the first close at least 21 days later.
Risk combines proximity, average absolute price movement, surprise variability, estimate availability and timing certainty. It does not score direction.
Exact public dates are used when stored. Missing estimates, timing and statement fields remain missing. No result or reaction is filled from a future observation.
Independent market research for education. Not investment advice, a recommendation, forecast, target or execution instruction.